#### Introducing the Ultimate Guide to Laboratory Test Utilization

What's in CLSI's GP 49, How to Use It, and Why It Works

Gary W. Procop, MD, MS Chairholder, CLSI GP49

# Who, Why, What, How

R Who:

- **Who wrote it:** Authors who are Legends
- **Who should do this work locally**

#### R Why:

- Section 2018 Section 20
- ম What: To Do. (Good recipes)

#### 

#### R How:

- CLSI Process This is a consensus document.
- Mumerous Examples
- ☑ To report your successes.

## Text Breakdown



- Foreword/ Introduction
   Scope/Background/Terminology
- Structure and Function
   Initial Framework/Organizational Approach/ Program Management
- Strategies and Tactics
   Causes/Countermeasures
- Analytics and Measures Measures/Analysis/Reporting
- Additional Considerations
   Problems & Barriers/Elements Needed for Success/Lessons Learned

### Foreword

Healthcare is changing.
Transaction-Based to Value-Based (Capitated)

Opportunities for Laboratory Leadership
 Re-define our role and value in the new system.
 More actively participate in the pre- and post-analytic space

Optimizing Testing
 Addresses under- and over-utilization.

## Introduction



R Scope

Initiating, developing, and maintaining an effective test utilization committee.

Rationale

Risk/Benefits

Useful to demonstrate *who* in your system will benefit

**R** Causes

CR Definitions

How to Do it Right (Anything Else Must Be Wrong)

ন্থ The correct test is ordered for the correct situation.

ম The specimen is collected correctly.

The laboratory performs the test in a precise, accurate and timely manner.

C3 Errors = repeats; untimely results = repeats/less-to-noneffective.

- Test result provides clinically useful information that is interpreted correctly and acted upon (promptly) and appropriately.
   Activating the *effector arm*
  - **G** Be part of the System

# Risks of Under-Utilization

Incorrect/Delayed Diagnosis
Late presentation = advanced disease; more costly to treat.

Quantification / increased length of stay

Patient dissatisfaction
 What should have been done --> Google it.

CR Liability exposure or fear of liability
 CR A cause of overutilization (Solution = guidelines)

## Structure/Function

Rainitial Framework

**Commitment** and Investment

Resources

**Organizational** Approach

Reversion of the American Amer

## Initial Framework

Right Sizing
 No "One Size Fits All"
 All Politics are Local

**Organizational and Individual Alignment** 

Nuts & Bolts
Meeting schedule
Responsibilities
Etcetera

Commitment & Investment

ন্থ Resides at all levels:

✓ Organizational Leadership

Real More than moral support will become necessary

🛯 Program Leadership

R Beware of Becoming a "Heroic Leader"

Cost Team Members

Real Committed, Engaged & Active.

Clinical and Laboratory Stakeholders
 Co-Creation is Key

Time is invested by allDocumented and Valued

## **Essential Resources**

Resources will be needed for:
 Project management
 Data collection & analysis
 Committee meeting preparation and participation
 Presentations & Meetings
 Clinical Stakeholders
 Institutional Leadership

🗷 Impact analysis

Report generation



Response of stakeholders throughout an organization to achieve the desired outcomes.

Multispecialty Utilization Teams
 Seek broad-input; respect diverse opinions.
 Open, collegial exchange -> Informed decision making

Engagement and Participation
 I need a hero: Champions are necessary.
 Clinical:Pathology Dyads can be effective.

Redical/Financial/ IT Knowledge

R Skill Set to Lead the Team

## Motivations & Incentives

ন্থ Traditional:

- Contain and Reduce Healthcare Expenditure.
  - Reprint Critical with capitation

#### Additional:

- Implementation of Best Practices (Do Good by doing Right)
  - ন্থ Improves/Preserves Engagement
  - Real Amprove Patient Care/Experience
  - Recrease Harm (e.g., Iatrogenic anemia)
- Alignment with payors
  - 🛯 Shared savings
- Address budgetary gaps.

# Sidebar: Positive Predictive Value

- R Nuns and Commercial Sex Workers

Test Specs: 95% Sensitivity/95% Specificity: Good Test, right?

Prevalence of Disease	Positive Predictive Value	Negative Predictive Value
1%	16%	99%
5%	50%	99%
10%	68%	99%
25%	86%	98%
50%	95%	95%

## The Team Composition

Remember to Tailor

Composition is dynamic, not static

#### ম Key Members Include:

- Pathologist & Doctoral-Level Scientist
- Clinicians & Nurses
- Administrators
- Genetic Counselors
- IT & Data Services
- 🥨 Quality
- Continuous improvement professionals
- **113** Financial Analysts
- Statisticians (or someone with equivalent knowledge)

## The Team's Work

To determine: Scope and Goals
To establish the agenda for meetings
Prioritize initiatives
Project management of initiatives
Collect and analyze data
Implement proposals and monitor change.
Track and report impacts (hopefully successes)

Reprogram management (Lobby for a program manager)

# Strategies/Tactics

(2



# Now what, again, are we trying to fix ?



# Inappropriate Test Selection

#### 

More frequently than necessary
 Result will not change within a given time frame.
 Examples: Lipid panel, HbA1c

Results will not change
 Example: Constitutional genetic tests

Provider is unaware of the results

# Inappropriate Test Selection

Based on the results of another tests
 Free T3, if TSH is normal; HCV antibody, if HCV RNA detected

- ✓ Based on the inability to interpret due results of another test
   ∞ Free PSA, if PSA <4 or >10 ng/ml.
- Based on patient demographics, location, time of year, sample type
   Rapid Strep without pharyngitis; *C. difficile* on formed stool; Influenza when out of season; lipid panel in the ED.
- Redundancy of results (inches versus centimeters)
   ESR and CRP; stool calprotectin and lactoferrin

# Inappropriate Test Selection

**3** Technical Problems

Aberrant listing (Numerical/Alphabetical) HIV2 listed before HIV1

Cognitive Problems

Realize tests

Ragnesium/Manganese;

R Crytococcal Antigen vs. Antibody,

Real Anti-thyroglobulin versus thyroglobulin.

# Inappropriate Test

#### <mark>ন্থে Misordered Test</mark>

Misunderstandings of Specific Indications

ন্থ Phenochromocytoma (Adults):

R Blood serotonin (incorrect) vs. urine metanephrine.

ন্থ Allergic Aspergillosis:

ন্থ Galactomannan (incorrect) versus Aspergillus IgE

Improper Menu or Order Set Configuration

R One mistake is multiplied and lasts a long time

Menu: Listing issues, sound alikes, rarely used tests
 Consider: Tiered ordering screens (Commonly used; specialty)

- Real Built in waste, for convenience

Inappropriate Test Procedure

Refficient Test Procedure

Unnecessary work (overprocessing) -> Delays

Real Example: Working up normal flora in microbiology.

Rest Procedure

Obsolete test/insensitive -> No diagnositic value -> Additional Testing Needs

**CR** Untimely Result

Example: Send-out CSF Gram stain -> poor patient care

Reflex Testing

CS Reviewing reflex testing to assure appropriateness

Erroneous or Misinterpreted Results

Series = Repeats; QC = Cost-effective practice

ন্থ Specimen Quality/Integrity Issues

Problems related to:

- Specimen Collection: QNS, mislabeling, poorly timed (when applicable) = Repeat
- Specimen Transport: Compromised integrity -> errors -> patient harm/repeats/ancillary testing.
- ℜ Specimen Processing: As above
- Problems related to patient condition (e.g., fasting)
- R Cognitive Problems
  - Misunderstanding (Consider interpretive comments).
  - Systems-Based Approach

Omission of Testing (Under-utilization)

- ন্থ Incomplete Testing for Diagnosis
  - 🕫 Initial
    - Example: Failure to test for <u>both</u> ceruloplasmin and copper for suspected Wilson's disease
  - CS Reflex:
    - Example: Failure to follow-up a positive HCV antibody test with an HCV RNA assay
- ন্থ Incomplete Testing for Monitoring
  - Chronic conditions/treatment:
    - R Diabetes control.
- Recommended Testing for Clinical Condition Not Performed.
  - C3 ER/PR/HER2 not performed on invasive ductal carcinoma.
  - 🛯 Malpractice issue.



Real Four Primary Strategies

**G** Education and Feedback

3 Test Order Control

Appropriate Selection and Application of Laboratory Testing Procedures

**Utilization of Test Results** 

# Strategies: Education and Feedback

#### Prospective (Limited Impact) Clinician, Patient, May Influence Consultation

ন্থ Decision Support গু Passive, Hard Stops, Advanced

Retrospective
 Clinician Profiling
 Compare like practices
 Inter-Institutional Benchmarking
 Compare similar institutions



Strategies: Test Order Control

Use of Test Orders / Order Sets
 Menu: Configuration is key
 Remove obsolete tests.
 Order Sets: Work to standardize within groups
 Review regularly

Reflex Testing / Algorithms
 Work to replace bundling within Order Sets with best practice reflex algorithms

Real Availability

- CS Tiered testing
- CS Privileging / Clinical Consultation Required
- 3 Lab-Order Only Hold/Review



#### Justification required

Limited to providers on select services

Orderable by all providers

## Analytics/Measures

Realization References and Revenues Rev

- Accurately captures relevant clinical and operations effects of the initiative
- Identifies and excludes clinical and operations outcomes unrelated to the initiative.
  - Example: Don't measure the impact of an initiative to decrease unnecessary influenza test as the season ends.
- Achieves statistical power

Is concise and easy to interpret

# Selected Analytical Approaches

- Renchmarking
- ন্থ Yield Analysis
- 🛯 Trend Analysis
- ෬ Repeat Testing Analysis
- 🛯 Sequential Testing Rates
- Guideline Conformance
   Guideline Conformance
   Conformace
   Co



# Calculating Cost Savings

R Decreased Operating Costs (Materials & Labor)

Decreased Patient Care Costs
 Decreased out-of-pocket expenses
 Increased patient satisfaction

- CR Decreased Managed Care Costs CR (Consider Shared Savings)
- Reduced Specimen Collection Costs
   Materials; and phlebotomist/nursing time
- Decreased Costs d/t False Positives
   Repeat testing; possible radiologic studies
   Additional provider time; lost time from work.



Other Impacts (Difficult to Quantify)

- Real Patient Satisfaction
  - S Fewer phlebotomy
  - Costs for phlebotomy/nursing
- Real Manual Clinical Quality
  - More efficient, timely diagnosis
  - Optimal diagnosis, treatment, and outcomes
  - G Fewer false positives
- Real Marcoved Value
  - Reduced length of stay
  - Appropriate use of consultations
  - G Fewer followups for false-positives



**Change** Management

ৰ Communications ও Notification / Feedback / Thanks

CR Employ Continuous Improvement Tools

R Good meeting practices



### Supplemental Appendices

A. Sample Test Utilization Project Charter

**R** B. Sample Action Plan Template

**CR** C. Sample Multiple Initiative Utilization Cost Worksheet

R D. Sample Single Initiative Utilization Worksheet

Recommendations for Laboratory Testing



